Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study
Not Applicable
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000020861
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Brief Summary
RR and disease control rate (DCR) were 1.3% and 29.6%, respectively. Median PFS and median survival time (MST) were 2.1 and 6.3 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active double cancers
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival
- Secondary Outcome Measures
Name Time Method Progression-free survival, Response rate, Disease control rate, Time to treatment failure, Adverse events, Relative dose intensity, Detail of subsequent treatment